Laura Panjwani

OncLive spoke with Bruce D. Cheson, MD, to gain a deeper understanding about the significance of the GADOLIN study results.

OncLive spoke with Jeffrey Jones, MD, MPH, to better understand the Study 119 results, as well as the role idelalisib and other novel targeted agents will play in CLL going forward.

Lead author Asher A. Chanan-Khan, MD, discusses the HELIOS trial, in which adding ibrutinib to bendamustine and rituximab lowered the risk of disease progression by 80% in patients with CLL.

Ruth M. O'Regan, MD, discusses two of her studies in HER2-positive breast cancer presented at ASCO 2015.

Laurie H. Glimcher, MD, discusses the promise of XBP1 inhibition as an immunotherapy strategy in ovarian cancer.

For insight on the potential of ONT-380 in HER2-positive breast cancer, OncLive spoke with the lead author of the primary phase Ib analysis, Erika P. Hamilton, MD.

Olanzapine (Zyprexa) demonstrated an improvement in antinausea effects in patients receiving concurrent highly emetogenic chemotherapy and radiation therapy for advanced stage head and neck and esophageal cancer when compared to fosaprepitant.

Risk of inflammation and cognitive impairment due to chemotherapy, often called "chemobrain", may be reduced by maintaining physical activity during treatment.

Many oncology professionals who treat patients on regorafenib are unfamiliar with how to manage and prevent hand-foot skin reaction.

Lead PERSIST-1 author Ruben A. Mesa, MD, deputy director of the Mayo Clinic Cancer Center in Scottsdale, Arizona, discussed the trial's results and pacritinib's potential to change the treatment paradigm for patients with myelofibrosis.

Jedd D. Wolchok, MD, discusses the unique design and goals of the CheckMate-067 trial, and what its results mean for patients with advanced melanoma going forward.

Sagar Lonial, MD, discusses the future of monoclonal antibodies in multiple myeloma.

Robert J. Mayer, MD, discusses pivotal phase III results for TAS-102 in colorectal cancer.

The identification of a deletion 20q in a patient with chronic lymphocytic leukemia may not indicate they have developed a myelodysplastic syndrome as was previously assumed.

At a recent FDA joint advisory committee meeting, members voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec as a treatment for patients with advanced melanoma.

To better understand the impact of the EORTC 18071 trial, the chances of approval in the adjuvant setting, and the challenges concerning the dosage and toxicity with ipilimumab, OncLive spoke with the study's lead author Jeffrey S. Weber, MD, PhD.

In a recent interview with AJHO, Sara A. Hurvitz, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer and what the future might hold.

Patients with diffuse large B-cell lymphoma who developed detectable circulating tumor DNA during surveillance were more than 200 times more likely to have their disease progress than those who did not have detectable ctDNA.

Immunotherapies and targeted therapies have led to significant strides in the treatment of patients with melanoma. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge. For further insight on optimizing the recent treatment breakthroughs in melanoma, OncLive spoke with Alan Bryce, MD, medical director of the Genomic Oncology Clinic at Mayo Clinic.

By targeting the HER2 protein's ability to transform cells, therapies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) have significantly extended the survival of women with HER2-positive breast cancer. However, major treatment challenges still remain for this breast cancer subtype, according to Ruth Lupu, PhD, professor of Laboratory Medicine and Pathology at Mayo Clinic.

Josep Tabernero, MD, PhD, discusses the potential of the antibody mixture Sym004 in mCRC, as well as other emerging trends in the management of colorectal cancer.

Charles S. Fuchs, MD, discusses the impact of the approval of ramucirumab in metastatic colorectal cancer and what further research is needed for the optimal utilization of the VEGFR-2 inhibitor.

In an interview with OncLive, John Radford, MD, discusses the impact of novel agents in non-Hodgkin lymphoma and what continued research is necessary to overcome treatment challenges.

While some patients with Hodgkin lymphoma require radiotherapy, the risks are not necessary for a large portion of patients who can experience long-term disease-free survival with chemotherapy alone, says John Radford, MD.

In an interview with OncLive, Charles M. Perou, MD, explains the importance of understanding and treating each subtype differently and why oncologists should be aware of the similarities between basal-like breast cancer and other non-breast cancer tumor types.

James P. Allison, PhD, was recently honored with two prestigious awards: the Science of Oncology Award from ASCO and the Pezcoller Foundation–AACR International Award for Cancer Research.

In an interview with OncLive, Robert C. Bast, Jr, MD, discussed his research using CA-125 levels and p53-autoantibodies as biomarkers for early detection of ovarian cancer.

Treatment with lenalidomide (Revlimid) versus placebo improved health-related quality of life (HRQoL) after 24 weeks for patients with myelodysplastic syndromes.

OncLive spoke with Guillermo Garcia-Manero, MD, regarding the significance of sotatercept and rigosertib and their potential as therapies in MDS.

OncLive sat down with F. Stephen Hodi, director, Melanoma Center, director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, to gain further insight into combination and sequencing strategies for patients with melanoma.